HealthFDA Wants Advisory Panel To Vote On Sarepta Muscle Wasting Drug Eteplirsen FDA staff wants the advisory panel to vote on Sarepta's eteplirsen wasting drug after reviewing its effectiveness. An advisory panel meeting will include the recommendations of the FDA.by Jereal Cawis
HealthHeart Disease Patients May Lower Heart Attack, Stroke Risk With Mediterranean Dietby Katherine Derla
HealthLiving In Places With Greenery May Lower Blood Pressure, Diabetes Riskby Catherine Cabral-Isabedra